Few additional pointers from the call.
Looking at customers as partners for growth. Non-linear triggers will be converting IPs into technology solutions
Use big data to improve Real World Evidence for clinical R & D to capture observations and inputs. They want create technology solutions that connect the dots for end to end clinical use cases
Will be rolling out new technology solutions based on their patents in FY 17
PharmaReady has around 100 customers, receiving good feedback and rolling out additional features based on it. In essence, competition for small and mid-sized is diffused
PharmaReady - Generates revenue in two ways
Licensing + Annual Maintenance Contract model
Service Delivery - Number of submissions, milestone based deliverables
They are investing in the right area and focussing on margin growth organically, but inorganic growth can happen in the form of non-linear triggers. Investments (cost) made for non-linear growth will be part of this year, will make money after 2 qtrs.
Middleeast growth will be flattish for SCM if not negative and there is no visibility into order book at this point of time
Reasons for Debt Expansion:
7% is because of forex fluctuation in the year
Loan from US & Singapore @ 5%
Promoter Load @ 7%
Ecron had debt on its books, carrying it on their books now
Loan to others: 8.5 Cr is long term loan and 172 Cr is short term (adv. tax, service tax, adv. to suppliers, pending accruals). This is not to earn interest
Not planning to write off goodwill, it will be on the books for now. No clear answer on number of years for amortization. Would like to hold it as an intangile asset for long term
Carrying 130 crores cash, will not use it to repay debt. Will use other lines of capital for re-paying debt
Grooming a membership community in life sciences and attending more global conferences
Disc: Invested recently